Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma

Main Article Content

Neal Bhatia, MD
Jonathon Kantor, MD
Lawrence Green, MD
Jonathon Weiss, MD
Cynthia Wilson, RN, BSN
Susan Cutler, DMD
Jayson Rieger, PhD, MBA
David K. Glover, ME, PhD
Pamela Rumney, RN, CCRC
Gary Goldenberg, MD


Basal Cell Carcinoma



1. Sveinbjørnsson, Baldur et al. “LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.” Future Medicinal Chemistry 9 12 (2017): 1339-1344.

2. Eike LM, Yang N, Rekdal Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015 Oct 27;6(33):34910-23.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>